Skip to main navigation

CVRx

Patients
BAROSTIM THERAPY for Heart Failure

Are heart failure symptoms impacting your life? You are not alone. Millions of people worldwide suffer from these life-altering symptoms. BAROSTIM THERAPY is an effective solution to safely reduce symptoms of heart failure.
Learn More

BAROSTIM NEO and You

BAROSTIM NEO is proven to safely reduce symptoms of heart failure.
Learn More

Patient Stories

Real stories from patients that have asked if the BAROSTIM NEO is right for them.
Learn More
Healthcare Professionals
Heart Failure Trial Results

BAROSTIM NEO addresses a significant unmet medical need in the treatment of heart failure.
Learn More

About BAROSTIM NEO

BAROSTIM NEO is an implantable device that is clinically proven to safely reduce symptoms of heart failure.
Learn More

Publications

CVRx is committed to the continued publication of clinical evidence supporting the benefit of BAROSTIM THERAPY for the treatment of heart failure.
Learn More

Reimbursement

CVRx provides full BAROSTIM THERAPY Patient Access Program support to all providers.
Learn More

Medical Education

Learn more about BAROSTIM THERAPY clinical evidence, patient selection and implant procedure from the experts.
Learn More

Clinical Research

CVRx is committed to the generation of clinical evidence, including investigator-sponsored research, to support the adoption and access to our therapies.
Learn More
About Us
Our Company

CVRx® is a leader in innovative technologies that address the unmet needs in cardiovascular diseases with safe and effective therapies.
Learn More

Our Team

We are proud of our reputation for attracting some of the brightest leaders in the medical technology industry.
Learn More

Newsroom

Latest press releases and company statements.
Learn More

Resources

Downloads are made available to provide background information about us, our products and the conditions they treat.
Learn More
Investors
Overview

Our life goal is to make yours better.
Learn More
News & Events
- News Releases
- Events
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Corporate Governance
Financial Information
IR Resources
Contact Us

Investors

News Releases

Year

Sep 17, 2021

CVRx Added to Russell 2000® and 3000® Indexes

Aug 04, 2021

CVRx Reports Second Quarter 2021 Financial and Operating Results

Jul 29, 2021

CVRx to Present at the Canaccord Genuity 41st Annual Growth Conference

Jul 21, 2021

CVRx to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call

Jul 12, 2021

CVRx Welcomes Veteran Life Science Industry Leader Martha Shadan to its Board of Directors

Jul 02, 2021

CVRx, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Jun 29, 2021

CVRx, Inc. Announces Upsized Pricing of Initial Public Offering

Mar 26, 2021

Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States

Mar 15, 2021

Fierce Medtech Names CVRx as One of its “Fierce 15” Companies

Jan 05, 2021

CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing

Print

Email Alerts

RSS Feeds

Contact IR

Patients

BAROSTIM THERAPY for Heart Failure
BAROSTIM NEO and You
Patient Stories

Healthcare Profesionals

Heart Failure Trial Results
About BAROSTIM NEO
Publications
Reimbursement

About Us

Investors
Overview
Our Team
Newsroom
Downloadable Images
Contact Us

Connect

Intellectual Property
Terms of Use
Privacy Policy
Cookie Policy
AdvaMed Code of Ethics
MedTech Europe Code of Ethics
Important Safety & Regulatory Information

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok